Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

three milestones in Roche collaboration

Gained rights to HuMax-CD4 and HuMax-TAC from Merck Serono and HuMax-IL8

through asset exchange with Medarex

Commenced seven new studies:

HuMax-EGFr - Phase III front line head and neck cancer study by DAHANCA

and Phase II non small cell lung cancer study

HuMax-CD20 - Phase II front line CHOP combination study in follicular

non-Hodgkin's lymphoma, 2 RA Phase III studies, Phase II relapsed

diffuse large B-cell lymphoma study

HuMax-CD38 Phase I/II multiple myeloma study

Achieved positive clinical trial results:

HuMax-CD20 Phase II RA data

Final HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) data

R1507 Phase I sarcoma data

Presented pre-clinical data:

Positive data for HuMax-HepC, HuMax-EGFr and HuMax-CD20

Unique mechanisms of action of HuMax-CD4 and HuMax-EGFr

Financial Highlights:

Cash position increased for fourth consecutive year

Achieved membership in OMXC20 index on the OMX Nordic Exchange

Copenhagen

2008 Guidance

We expect to significantly expand development in 2008 in our clinical and pre-clinical programs, including plans to initiate 17 new clinical studies, filing our first biologics license application and selecting two new clinical candidates. We will pay development costs for the new and ongoing pivotal studies in HuMax-CD4 and HuMax-EGFr. Under our collaboration with GSK, we will fund half the development costs for the trials with HuMax-CD20. We expect to continue our increasing level of discovery and pre-clinical work in 2008, developing antibody products for a variety of new and existing disease targets. Finally, the 2008 projections include operating costs from the newly acquired antibody manufacturing facility.

Due to these expanded activities, Genmab's operating costs are expected to be higher in 2008 than in 2007. In combination with increasing re
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ... estimates and forecasts of the revenue and share ...
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... Improve PCR product yield and specificity for ... Amplification Reactions with,Perfect Match PCR Enhancer ... Certain PCR amplification systems produce multiple product bands ... priming events, template secondary,structures, or suboptimal PCR conditions. ...
... use in transplantation studies , hNT BlueNeurons ... Michael McGrogan * Guadalupe Gonzalez * Waldemar Lernhardt ... hNT BlueNeurons express beta-galactosidase at high levels and,are ... stably transfected with a,lacZ gene expression vector. Because ...
... genomic targets up to 19 kb , Enhanced ... , Michael Borns Holly Hogrefe ,Stratagene , Improve ... by making simple modifications to PCR reaction,conditions. In this ... be amplified up to 19 kb in length. , ...
Cached Biology Technology:Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 2Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 3Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 4Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 5Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 6hNT BlueNeurons Express b-Galactosidase at High ,Levels 2hNT BlueNeurons Express b-Galactosidase at High ,Levels 3hNT BlueNeurons Express b-Galactosidase at High ,Levels 4hNT BlueNeurons Express b-Galactosidase at High ,Levels 5Enhanced Amplification of Long Targets with PfuTurbo DNA,Polymerase 2Enhanced Amplification of Long Targets with PfuTurbo DNA,Polymerase 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... a bubble while washing the dishes and you,re likely ... the soapy sphere formed. A few years ago, researchers ... pioneered a method* using a microscopic fluidic (microfluidic) device ... called liposomes from phospholipids, the fat complexes that are ...
... released this week in The Lancet Infectious Diseases ... a bacterial infection that causes pneumonia, meningitis and sepsis ... disease, a blood disorder prevalent in African children that ... The study underscores the critical need for use of ...
... won two national Federal Laboratory Consortium awards for ... Cray Inc., and solar energy supplier Stirling Energy ... to present the Excellence in Technology Transfer Awards ... The consortium is a nationwide network of technology ...
Cached Biology News:NIST, Maryland researchers COMMAND a better class of liposomes 2Vaccines preventing pneumococcal disease protect African children with sickle-cell disease 2Vaccines preventing pneumococcal disease protect African children with sickle-cell disease 3Sandia wins 2 national technology transfer awards for work with Cray, Stirling Energy Systems 2
... of a series of media originally developed at ... al. for the large scale propagation of cells ... primarily used for the growth and maintenance of ... of viruses in these cell lines. One of ...
... Trx•Tag™ Ek Adaptor encodes a T7 promoter, ... (rbs), ATG translation initation codon, and an ... a 109 aa sequence that encodes thioredoxin. ... to enhance solubility of many proteins that ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
Biology Products: